Texas Clinical Trials Report — May 2026

For Texans considering participation in clinical research, May 2026 presents a crucial window of opportunity, particularly for those interested in trials that are nearing their enrollment deadlines. Across the state, 336 clinical trials are scheduled to close within the next 90 days. This urgency extends to healthy volunteers, with 46 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals keen on contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various types of cancer, heart conditions, and metabolic disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor
• Heart failure
• Acute myeloid leukemia
• Breast cancer
• Obesity
• Metastatic cancer
• Diabetic foot ulcer (DFU)
• Endometrial cancer

New Research Horizons in Texas

This month, Texas welcomed 28 new clinical trials, a notable decrease compared to the 92 trials that launched in March 2026. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 4,848 clinical trials currently recruiting across 177 cities and 4,366 research sites. The new studies this month bring significant opportunities, particularly in metabolic health and chronic conditions, often sponsored by major pharmaceutical companies and leading academic institutions.

Leading the charge in new research are several high-profile Phase 2, 3, and 4 studies from major pharmaceutical companies and leading academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to vision impairments and infectious diseases.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• Novo Nordisk A/S is also behind two Phase 3 studies focused on obstructive sleep apnoea: NCT07571005, "AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea," and NCT07571109, "AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea." Both studies aim to enroll 300 participants each to evaluate the efficacy and safety of NNC0487-0111.
• The University of Colorado, Denver is sponsoring NCT07569250, an interventional study titled "Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization," which aims to enroll 7,220 participants to improve colorectal cancer screening rates.
• Ohio State University is leading NCT07567040, a Phase 4 study named "Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial." This trial will involve 664 participants and test whether the onset of nearsightedness (myopia) is delayed in children randomized to nightly drops of 0.05% atropine compared to a placebo. This study includes children as participants.
• Senju USA, Inc. is sponsoring NCT07565103, a seamless Phase 1/2 trial on "Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis," seeking 426 participants.
• The University of Texas Health Science Center, Houston is sponsoring NCT07573202, a randomized controlled trial comparing "Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh a Randomized Controlled Trial to Evaluate Hypersensitivity Reactions in Shoulder Surgery," with 350 participants.

Geographic Reach and Participation Opportunities

The majority of new research initiatives this month are concentrated in Texas's largest metropolitan areas. Houston saw the highest number of new trials with 16 openings, followed by San Antonio and Dallas, each with 7 new trials. Other cities across the state also saw new trial launches, including El Paso (4), Sugar Land (3), and Austin (3). This distribution ensures that residents in major urban centers have broad access to cutting-edge research opportunities.

New studies are exploring a range of conditions, from widespread health challenges to more specific areas. This month's new trials are targeting:

• Obesity
• Obstructive sleep apnoea
• Overweight
• Anorexia nervosa
• Bacterial conjunctivitis
• Cerebral palsy
• Atypical anorexia nervosa
• Clear cell renal cell carcinoma

The types of interventions being studied are varied, with drug trials leading the way, accounting for 16 of the new trials. Other new studies include behavioral interventions, medical devices, biological treatments, and dietary supplements.

Diverse Participation: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 28 new trials launched this month, 21 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 6 new trials are open to children, offering opportunities for younger participants to engage in research that could benefit their age group. 2 trials are female-only, and 1 is male-only, addressing specific health needs within these demographics.

For individuals without a specific medical condition, there are significant opportunities to contribute. 7 of the 28 new trials this month are actively seeking healthy volunteers. Across Texas, a total of 513 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions and industry sponsors continue to play vital roles in Texas's research ecosystem. Novo Nordisk A/S is a prominent industry sponsor, leading 4 of the new trials. M.D. Anderson Cancer Center is also a significant academic sponsor with 3 new trials, alongside other institutions like Baylor College of Medicine and Cook Children's Health Care System. These collaborations ensure a robust and diverse research landscape.

As we move through May, the focus will likely remain on the ongoing enrollment in these significant Phase 2, 3, and 4 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Texas.